FeesSafety
Pluang+

Virtuix secures 27th patent, boosting its full-body VR simulation tech and market lead.

Company Fundamentals
29 Oct 2026, 16:17 WIB
GlobeNewsWire
View Source
Bullish
Virtuix secures 27th patent, boosting its full-body VR simulation tech and market lead.

Virtuix Holdings Inc. has received approval for its 27th U.S. patent, covering innovative footwear technology that enhances movement on omni-directional treadmills used in its Omni One VR platform. This patent strengthens Virtuix's intellectual property portfolio, creating barriers for competitors in gaming, enterprise, healthcare, and defense markets. The Omni One platform is recognized for its advanced, natural multi-directional movement in virtual environments, supporting Virtuix's growth strategy across multiple sectors. The company continues investing in R&D to expand its full-body simulation technology and market presence.

Virtuix's recent patent milestone offers context for readers interested in technology innovation. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 19:13 WIB: out of 150 priced stocks, 21 rose and 127 fell. Notable movers include CRWD at USD 247.95 with a 1-day change of -7.02% and typical hold time of 98 days, PANW at USD 367.02 down 6.96% with 82 days hold time and 91% buy order activity, and TEAM at USD 205.75 down 6.53% with a 65-day hold time and 100% buy order activity.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
46 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
46 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App